All In Biotech

Drug Trial Radar · NCT01080807

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder

Last checked: Nov 20, 2026Latest source record: Jun 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 385 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

385

Actual

Start

Mar 2010

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
CephalonIndustry
Sponsor type
Industry
First posted
Mar 4, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved clinical condition late in the shift, including the commute home.

Conditions

  • Excessive Sleepiness

Interventions

  • ArmodafinilDrug

    At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.

  • Matching PlaceboDrug

    At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at EndpointTime frame: Baseline and week 6 (or last observation after baseline)

Locations

63 sites in 1 country. Site status is shown where the registry gives one.

  • REM Medical Sleep Center

    Phoenix, Arizona

  • REM Medical Clinical Research

    Tucson, Arizona

  • Central Arkansas Research

    Hot Springs, Arkansas

  • Clinical Study Centers LLC

    Little Rock, Arkansas

  • Peninsula Sleep Center

    Burlingame, California

  • Avastra Clinical Trials

    Fountain Valley, California

  • Pacific Sleep Medicine Services Inc

    Los Angeles, California

  • Southwestern Research Inc

    Pasadena, California

  • Pacific Sleep Medicnie Services Inc

    Redlands, California

  • Stanford University Medical Center

    Redwood City, California

  • Dormir Clinical Trials, Inc.

    San Diego, California

  • Southwestern Research Inc

    Santa Ana, California

  • St Johns Medical Plaza Sleep Disorders Center

    Santa Monica, California

  • PAB Clinical Research

    Brandon, Florida

  • MD Clinical

    Hallandale, Florida

  • Compass Research LLC

    Orlando, Florida

  • Broward Research Group

    Pembroke Pines, Florida

  • Miami Research Associates

    South Miami, Florida

  • Florida Sleep Institute

    Spring Hill, Florida

  • Clinical Research Group of St Petersburg

    St. Petersburg, Florida

  • SomnoMedics

    Tampa, Florida

  • Neurotrials Research Inc

    Atlanta, Georgia

  • Sleep Disorders Center of Georgia-Peachtree

    Atlanta, Georgia

  • Sleep Disorders Center of Georgia-Gainesville

    Gainesville, Georgia

  • Sleepmed Inc

    Macon, Georgia

  • Chicago Research Center

    Chicago, Illinois

  • Suburban Lung Associates

    Elk Grove Village, Illinois

  • The Center for Sleep and Wake Disorders d/b/a Midwest Neuro

    Danville, Indiana

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • Rehabilitation Associates of Indiana

    Indianapolis, Indiana

  • Goldpoint Clinical Research

    Indianapolis, Indiana

  • University of Iowa Hospitals

    Iowa City, Iowa

  • Vince and Associates Clinical Research

    Overland Park, Kansas

  • Community Research

    Crestview, Kentucky

  • Kentucky Research Group

    Louisville, Kentucky

  • Helene A. Emsellem, MD

    Chevy Chase, Maryland

  • Sleep Health Center

    Brighton, Massachusetts

  • St Mary's of Michigan

    Saginaw, Michigan

  • The Center for Sleep Medicine

    Hattiesburg, Mississippi

  • Washington University Sleep Medicine Center

    St Louis, Missouri

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.